The health care burden of high grade chronic obstructive pulmonary disease in Korea: Analysis of the Korean Health Insurance Review and Assessment Service data

International Journal of COPD

Volumn 8, Issue , 2013, Pages 561-568

  Kim, Jin Hee ^a   Rhee, Chin Kook ^b   Yoo, Kwang Ha ^c   Kim, Young Sam ^d   Lee, Sei Won ^e   Park, Yong Bum ^f   Lee, Jin Hwa ^g   Oh, Yeon Mok ^e   Lee, Sang Do ^e   Kim, Yuri ^h   Kim, Kyung Joo ^h   Yoon, Hyoung Kyu ⁱ  

^a National Evidence Based Healthcare Collaborating Agency   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Konkuk University School of Medicine   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e University of Ulsan College of Medicine   (South Korea)

^f Hallym University   (South Korea)

^g Ewha Womans University School of Medicine   (South Korea)

^h National Strategic Coordinating Center for Clinical Research   (South Korea)

ⁱ The Catholic University of Korea   (South Korea)

Author keywords

COPD; Health care utilization; Medical cost; Population characteristics

Indexed keywords

CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; LONG ACTING DRUG; LONG ACTING MUSCARINIC RECEPTOR BLOCKING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; SHORT ACTING BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; SHORT ACTING DRUG; SHORT ACTING MUSCARINIC RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG COST; DRUG USE; FEMALE; HEALTH CARE UTILIZATION; HEALTH SERVICE; HOSPITALIZATION; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MORTALITY; NATIONAL HEALTH INSURANCE; PREVALENCE; TERTIARY HEALTH CARE;

COPD; HEALTH CARE UTILIZATION; MEDICAL COST; POPULATION CHARACTERISTICS;

ADULT; AGED; AGED, 80 AND OVER; DATA MINING; DISEASE PROGRESSION; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HEALTH SERVICES; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; INSURANCE CLAIM REVIEW; LINEAR MODELS; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REPUBLIC OF KOREA; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84887964911     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S48577     Document Type: Article

References (22)

1. Halpin DM, Miravitlles M. Chronic obstructive pulmonary disease: the disease and its burden to society. Proc Am Thorac Soc. 2006;3(7): 619-623.
2. Jensen HH, Godtfredsen NS, Lange P, Vestbo J. Potential misclassification of causes of death from COPD. Eur Respir J. 2006;28(4): 781-785.
3. Jensen MB, Fenger-Grøn M, Fonager K, Omland Ø, Vinding AL, Hansen JG. Chronic obstructive pulmonary disease involves substantial health-care service and social benefit costs. Dan Med J. 2013;60(1): A4557.
4. Miravitlles M, Murio C, Guerrero T, Gisbert R. Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest. 2003;123(3):784-791.
5. Detournay B, Pribil C, Fournier M, et al; SCOPE Group. The SCOPE study: health-care consumption related to patients with chronic obstructive pulmonary disease in France. Value Health. 2004;7(2):168-174.
6. Jones PW. Health status and the spiral of decline. COPD. 2009;6(1): 59-63.
7. Hurst JR, Vestbo J, Anzueto A, et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128-1138.
8. Global Initiative for Chronic Obstructive Lung Disease [homepage on the Internet]. Global strategy for the diagnosis, management and prevention of COPD. 2011 [updated Feb 2013]. Available from: http://www.goldcopd.org/Guidelines/guidelines-resources.html.
9. Lee SY, Jung KY, Lee IK, et al; Korean Epilepsy Society. Prevalence of treated epilepsy in Korea based on national health insurance data. J Korean Med Sci. 2012;27(3):285-290.
10. Korean National Health Insurance Cooperation Seoul. Annual Report of National Health Insurance Statistics, 2008. Seoul: Division of statistical analysis, Korean National Health Insurance Cooperation; 2008. Available from: http://www.nhis.or.kr/portal/site/main/MENU_WBDDG02/. Accessed August 2013.
11. Prescott E, Lange P, Vestbo J. Socioeconomic status, lung function and admission to hospital for COPD: results from the Copenhagen City Heart Study. Eur Respir J. 1999;13(5):1109-1114.
12. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J. 2006;28(6):1245-1257.
13. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32(4):962-969.
14. Gan WQ, Man SF, Sin DD. The interactions between cigarette smoking and reduced lung function on systemic inflammation. Chest. 2005;127(2):558-564.
15. Burgel PR, Paillasseur JL, Caillaud D, et al; Initiatives BPCO Scientific Committee. Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur Respir J. 2010;36(3): 531-539.
16. de Miguel Diez J, Carrasco Garrido P, García Carballo M, et al. Determinants and predictors of the cost of COPD in primary care: a Spanish perspective. Int J Chron Obstruct Pulmon Dis. 2008;3(4): 701-712.
17. Jansson SA, Andersson F, Borg S, Ericsson A, Jönsson E, Lundbäck B. Costs of COPD in Sweden according to disease severity. Chest. 2002;122(6):1994-2002.
18. Faganello MM, Tanni SE, Sanchez FF, Pelegrino NR, Lucheta PA, Godoy I. BODE index and GOLD staging as predictors of 1-year exacerbation risk in chronic obstructive pulmonary disease. Am J Med Sci. 2010;339(1):10-14.
19. Masa JF, Sobradillo V, Villasante C, et al. Costes de la EPOC en España. Estimación a partir de un estudio epidemiológico poblacional. [Costs of chronic obstructive pulmonary disease in Spain. Estimation from a population-based study.] Arch Bronconeumol. 2004;40(2):72-79. Spanish.
20. Hoogendoorn M, Feenstra TL, Hoogenveen RT, Al M, Mölken MR. Association between lung function and exacerbation frequency in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2010;5: 435-444.
21. Menn P, Heinrich J, Huber RM, et al; KORA Study Group. Direct medical costs of COPD-an excess cost approach based on two population-based studies. Respir Med. 2012;106(4):540-548.
22. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320(7245): 1297-1303.